Study wrapper · #474
Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.
Editor's note
This cross-sectional online survey of 411 adults using semaglutide or tirzepatide for at least three months examined what drives treatment satisfaction beyond weight loss. Using a validated satisfaction measure, the authors found that fewer side-effect limitations, greater satiety, improved mood, and higher physical activity were independently associated with higher satisfaction, while the amount of BMI reduction lost statistical significance after adjustment. As a self-selected, self-reported snapshot from online communities, this design is prone to selection and recall bias and cannot establish cause or direction. It does not compare the two drugs' efficacy. For semaglutide and tirzepatide readers, the takeaway is that in this sample tolerability and day-to-day wellbeing tracked satisfaction more closely than pounds lost, a patient-experience signal rather than a clinical-outcome finding.
Plain-language abstract
This survey asked 411 adults taking semaglutide or tirzepatide for at least three months what made them satisfied with treatment. Beyond weight loss, people who had fewer side-effect limitations, felt fuller, had better mood, and were more physically active reported higher satisfaction. Interestingly, the actual amount of weight lost was not independently linked to satisfaction once other factors were considered. Because participants were recruited online and reported their own experiences, the results may not represent everyone and cannot prove what causes what. The main message is that how people feel day to day, especially side effects and appetite, mattered as much as the number on the scale.